{"id":878163,"date":"2025-08-22T05:03:07","date_gmt":"2025-08-22T09:03:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/"},"modified":"2025-08-22T05:03:07","modified_gmt":"2025-08-22T09:03:07","slug":"natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/","title":{"rendered":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdecimal { list-style-type: decimal }\n.bwmarginl2 { margin-left: 60px }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation<\/b><\/p>\n<p class=\"bwalignc\"><i>Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints, and enriched clinical and imaging records<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54311568&amp;newsitemid=20250822585264&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=32f5cf0ec12f0e4ed5e682f6e1b55c17\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision support. The platform features a modular, multimodal architecture composed of three integrated layers:<\/p>\n<ol class=\"bwlistdecimal\">\n<li><b>Data foundation layer<br \/>\n<br \/><\/b>At its core is one of the largest longitudinal, multimodal oncology datasets ever compiled, purpose-built for AI training. This includes de-identified data from more than 250,000 tumor exomes and over 1 million longitudinal plasma timepoints, enriched with clinical records, treatment histories, digital imaging, expression profiling and outcomes data. This high-fidelity dataset enables scalable, AI-ready model development.<\/p>\n<\/li>\n<li><b>Core model layer<br \/>\n<br \/><\/b>Leveraging over 1 billion parameters, the core AI foundation model is trained on de-identified Signatera\u2122 and Altera\u2122 datasets and integrates genomic, clinical, and imaging modalities. It is designed to power discovery in multiple domains, including biomarker development, patient stratification and therapeutic response prediction.<\/p>\n<\/li>\n<li><b>Application layer<br \/>\n<br \/><\/b>Several AI-driven applications support clinical decision-making and drug development:<\/p>\n<\/li>\n<\/ol>\n<ul class=\"bwlistcircle bwmarginl2\">\n<li><b>Digital Patient Simulator<\/b>: Virtually simulates patients for treatment optimization, such as suggesting next-line therapies and de-escalation opportunities. It can also predict patient outcomes.\n<\/li>\n<li><b>Real-Time Trial Matching<\/b>: Uses molecular and clinical data to identify trial-eligible patients and accelerate recruitment. This engine can also simulate virtual trials to optimize study design and reduce development risk.\n<\/li>\n<li><b>NeoPredict<\/b>: An advanced algorithm that predicts individual immunotherapy responses based on tumor genomics and neoantigen presentation.\n<\/li>\n<\/ul>\n<p>\nTwo recent pilot programs of the digital patient simulator demonstrated excellent performance, supporting its potential to enhance clinical decision making in oncology. Results from the first pilot showed that Natera\u2019s algorithm can accurately recommend immunotherapy based on real-world electronic health record data. The second pilot showed outperformance of both tumor mutational burden and standalone pathology-based metrics in predicting immunotherapy response.<\/p>\n<p>\n\u201cThese new tools represent a major leap forward in our ability to design next-generation diagnostics and therapeutics,\u201d said Steve Chapman, CEO of Natera. \u201cBy combining our unparalleled data assets with sophisticated AI models built entirely in-house, we\u2019re establishing long-term differentiators that will shape the future of precision medicine. The early results are extremely encouraging, and we believe the potential to transform patient care is substantial.\u201d<\/p>\n<p><b>About Natera<\/b><\/p>\n<p>\nNatera\u2122 is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54311568&amp;newsitemid=20250822585264&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=2&amp;md5=281cba967f4d54e8b71384da64ff23e8\">www.natera.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in &#8220;Risk Factors&#8221; in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2Finvestors&amp;esheet=54311568&amp;newsitemid=20250822585264&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=3&amp;md5=2a398ecaf1d17999526c46c2621cc28d\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54311568&amp;newsitemid=20250822585264&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=b8d9f99d86f67b3ee4c4cff7d40f47bd\">www.sec.gov<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250822585264\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250822585264\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<br \/>\n<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Pharmaceutical Oncology Data Management Technology Artificial Intelligence Genetics Health Technology Clinical Trials Science Biotechnology Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250822585264\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints, and enriched clinical and imaging records AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision support. The platform features a modular, multimodal architecture composed of three integrated layers: Data foundation layer At its core is one of the largest longitudinal, multimodal oncology datasets ever compiled, purpose-built for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-878163","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints, and enriched clinical and imaging records AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision support. The platform features a modular, multimodal architecture composed of three integrated layers: Data foundation layer At its core is one of the largest longitudinal, multimodal oncology datasets ever compiled, purpose-built for &hellip; Continue reading &quot;Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-22T09:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation\",\"datePublished\":\"2025-08-22T09:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/\"},\"wordCount\":756,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/\",\"name\":\"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-08-22T09:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/","og_locale":"en_US","og_type":"article","og_title":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Market Newsdesk","og_description":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints, and enriched clinical and imaging records AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision support. The platform features a modular, multimodal architecture composed of three integrated layers: Data foundation layer At its core is one of the largest longitudinal, multimodal oncology datasets ever compiled, purpose-built for &hellip; Continue reading \"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-22T09:03:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation","datePublished":"2025-08-22T09:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/"},"wordCount":756,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/","name":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-08-22T09:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250822585264r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-launches-proprietary-ai-foundation-models-to-accelerate-diagnostic-and-therapeutic-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=878163"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=878163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=878163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=878163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}